Induction of Spindle Multipolarity by Centrosomal Cluster Inhibition

por Krämer, Alwin, Raab, Marc S., Rebacz, Blanka
Publicado 2008

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

por Rasche, Leo, Kortüm, K. Martin, Raab, Marc S., Weinhold, Niels
Publicado 2019

Pathway-Directed Therapy in Multiple Myeloma

por John, Lukas, Krauth, Maria Theresa, Podar, Klaus, Raab, Marc-Steffen
Publicado 2021

Novel immunotherapies in multiple myeloma – chances and challenges

por Rasche, Leo, Wäsch, Ralph, Munder, Markus, Goldschmidt, Hartmut, Raab, Marc S.
Publicado 2021

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop

por Lutz, Raphael, Friedrich, Mirco, Raab, Marc Steffen, Weinhold, Niels, Goldschmidt, Hartmut
Publicado 2021

Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

por Raab, Marc S., Zamagni, Elena, Manier, Salomon, Rodriguez‐Otero, Paula, Schjesvold, Fredrik, Broijl, Annemiek
Publicado 2023

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Mye...

por Sauer, Sandra, Kriegsmann, Katharina, Nientiedt, Cathleen, Schmitt, Anita, Müller-Tidow, Carsten, Raab, Marc-Steffen, Kauer, Joseph
Publicado 2023

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

por Sachpekidis, Christos, Kopp-Schneider, Annette, Merz, Maximilian, Jauch, Anna, Raab, Marc-Steffen, Goldschmidt, Hartmut, Dimitrakopoulou-Strauss, Antonia
Publicado 2020

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response

por Lehners, Nicola, Becker, Natalia, Benner, Axel, Pritsch, Maria, Löpprich, Martin, Mai, Elias Karl, Hillengass, Jens, Goldschmidt, Hartmut, Raab, Marc‐Steffen
Publicado 2017

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review

por Mohty, Mohamad, Cavo, Michele, Fink, Leah, Gonzalez‐McQuire, Sebastian, Leleu, Henri, Mateos, Maria‐Victoria, Raab, Marc S., Schoen, Paul, Yong, Kwee
Publicado 2019

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review

por Hájek, Roman, Gonzalez-McQuire, Sebastian, Szabo, Zsolt, Delforge, Michel, DeCosta, Lucy, Raab, Marc S, Bouwmeester, Walter, Campioni, Marco, Briggs, Andrew
Publicado 2020

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)

por Sachpekidis, Christos, Merz, Maximilian, Raab, Marc-Steffen, Bertsch, Uta, Weru, Vivienn, Kopp-Schneider, Annette, Jauch, Anna, Goldschmidt, Hartmut, Dimitrakopoulou-Strauss, Antonia
Publicado 2021

COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view

por von Metzler, Ivana, Campe, Julia, Huenecke, Sabine, Raab, Marc S., Goldschmidt, Hartmut, Schubert, Ralf, Rabenau, Holger F., Ciesek, Sandra, Serve, Hubert, Ullrich, Evelyn
Publicado 2021

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from th...

por Kauer, Joseph, Freundt, Emma P., Schmitt, Anita, Weinhold, Niels, Mai, Elias K., Müller-Tidow, Carsten, Goldschmidt, Hartmut, Raab, Marc S., Kriegsmann, Katharina, Sauer, Sandra
Publicado 2023

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

por Hájek, Roman, Delforge, Michel, Raab, Marc S., Schoen, Paul, DeCosta, Lucy, Spicka, Ivan, Radocha, Jakub, Pour, Ludek, Gonzalez‐McQuire, Sebastian, Bouwmeester, Walter
Publicado 2019

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

por Baertsch, Marc-Andrea, Fougereau, Mathilde, Hielscher, Thomas, Sauer, Sandra, Breitkreutz, Iris, Jordan, Karin, Müller-Tidow, Carsten, Goldschmidt, Hartmut, Raab, Marc-Steffen, Hillengass, Jens, Giesen, Nicola
Publicado 2021

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma

por John, Lukas, Miah, Kaya, Benner, Axel, Mai, Elias K., Kriegsmann, Katharina, Hundemer, Michael, Kaudewitz, Dorothee, Müller-Tidow, Carsten, Jordan, Karin, Goldschmidt, Hartmut, Raab, Marc S., Giesen, Nicola
Publicado 2023

P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND RE...

por Piasecki, Julia, Desai, Keyur, Courtney, Carolyn, Thompson, Ethan, Pratt, James, Raje, Noopur, Patel, Krina, Raab, Marc S., Cook, Mark, Simonsen, Katy, Popa Mckiver, Mihaela, Kaiser, Shari, Martin, Nathan
Publicado 2023

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

por Wagner, Verena, Hose, Dirk, Seckinger, Anja, Weiz, Ludmila, Meißner, Tobias, Rème, Thiery, Breitkreutz, Iris, Podar, Klaus, Ho, Anthony D., Goldschmidt, Hartmut, Krämer, Alwin, Klein, Bernard, Raab, Marc S.
Publicado 2014

Multiple myeloma: patient outcomes in real‐world practice

por Yong, Kwee, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Raab, Marc S., Schoen, Paul, Cavo, Michele
Publicado 2016